Receptors, Pathways, Messengers & Clinical Relevance
A complete academic guide to how cells communicate — from ligand–receptor binding and the four modes of intercellular communication through GPCR and RTK mechanisms, all major second messengers, the MAPK/ERK, PI3K/Akt/mTOR, JAK/STAT, Wnt, Notch, and Hedgehog pathways, signal amplification, feedback regulation, cross-talk, and the pharmacological and clinical consequences of pathway dysregulation in cancer, metabolic disease, and autoimmunity.
No cell in the human body functions in isolation. A hepatocyte regulating glucose output, a T lymphocyte detecting a pathogen, a developing neuron navigating its path through a crowded brain, a cardiomyocyte timing its contraction — every one of these specialised behaviours is governed by molecular conversations conducted at the cell’s surface and inside its cytoplasm, in real time, at extraordinary speed and precision. Cell signalling is the molecular language of multicellular life. Understand it and you understand how the body maintains homeostasis, how drugs work, and — critically — how cancer subverts the normal conversation to its own ends.
Signal transduction is the molecular relay that converts an extracellular signal — a hormone, a growth factor, a neurotransmitter, a contact signal from a neighbouring cell — into a specific cellular response. The language it uses is primarily the language of protein chemistry: conformational changes, phosphorylation, ubiquitination, protein–protein interactions, and regulated protein degradation. As StatPearls’ overview of cellular receptors notes, cells communicate through gap junctions, juxtacrine signalling, or secreted chemical messengers, with each mode adapted to a specific biological context and range of action. This guide unpacks all of these mechanisms systematically, from the receptor at the cell surface to the transcription factor in the nucleus, building the conceptual map of cell signalling that every biology, biochemistry, pharmacology, and medical student needs.
Cell Signalling — Core Principles and the Three-Stage Framework
Every signalling event — from adrenaline triggering a fight-or-flight cardiac response within milliseconds to a developmental morphogen gradient establishing the body axis over hours — shares a common three-stage architecture. This framework organises the seemingly bewildering complexity of hundreds of different signalling pathways into a coherent conceptual structure.
Stage 1 — Reception
A signal molecule (the first messenger or ligand) binds to a specific receptor, either on the cell surface or inside the cell. The receptor is typically highly selective — binding one or a small number of chemically related ligands with high affinity (nanomolar to picomolar Kd in many cases). Binding causes a conformational change in the receptor that initiates signalling. The specificity of reception determines which cells can respond: only cells expressing the appropriate receptor can detect a given signal — a key principle in tissue-targeted pharmacology.
Stage 2 — Transduction
The receptor-ligand interaction triggers a cascade of intracellular molecular events — signal transduction — that converts, routes, amplifies, and integrates the initial signal. Transduction typically involves sequential protein–protein interactions, enzymatic modifications (phosphorylation, GTP exchange, ubiquitination), generation of diffusible second messengers, and changes in protein localisation. The cascade is not a simple linear relay but a network with branching, amplification, feedback, and cross-talk at every level.
Stage 3 — Response
The transduced signal ultimately reaches its cellular targets and produces a specific cellular response. Responses occur on different timescales and in different compartments: fast responses include ion channel opening (milliseconds), cytoskeletal rearrangement, enzyme activation, and exocytosis. Slower responses involve altered gene transcription (minutes to hours) producing new proteins that change cell behaviour durably. The nature of the response depends not only on the signalling pathway activated but on the cell type, its developmental state, and the context of concurrent signals.
Modes of Cell Signalling — Range, Speed, and Molecular Mechanism
The physical distance a signal must travel and the biological context requiring rapid versus sustained responses have driven the evolution of five distinct modes of cell-to-cell communication, each with characteristic molecular machinery, timescale, and biological role.
Self-Stimulation — the Cell Signals Itself
A cell secretes a signal molecule that binds receptors on its own surface, enabling self-stimulation. Autocrine signalling amplifies and sustains a cell-autonomous response once initiated. During normal immune activation, T cells activated by antigen-presenting cells upregulate IL-2 receptor expression and secrete IL-2, creating an autocrine loop that drives their own proliferation. Cancer cells frequently exploit autocrine signalling to achieve growth factor independence — one of the Hallmarks of Cancer — by simultaneously expressing growth factors and their receptors, bypassing the need for external mitogenic signals. EGF/EGFR autocrine loops are common in breast, lung, and colorectal cancers.
Local Signals — Neighbouring Cells Within Diffusion Range
A cell releases signalling molecules that diffuse through the extracellular space to act on nearby cells, typically within a tissue. The signal is not amplified by the bloodstream and therefore has a limited range — determined by the diffusion coefficient of the molecule, its rate of degradation, and its affinity for extracellular matrix components. Paracrine signals are critical in embryonic development — where morphogen gradients (graded concentrations of Wnt, BMP, FGF, Shh) specify cell fate at different positions — in neurotransmission (at chemical synapses), in inflammatory responses (histamine from mast cells, prostaglandins from macrophages), and in tissue repair (VEGF from hypoxic cells stimulating local angiogenesis).
Long-Range Signals — Hormones via the Bloodstream
Endocrine signals are hormones secreted by specialised glands into the bloodstream, which distributes them throughout the body to act on target cells expressing the appropriate receptor. Endocrine signalling can coordinate responses across distant organs simultaneously — insulin from pancreatic β-cells simultaneously increases glucose uptake in muscle, inhibits hepatic gluconeogenesis, and promotes lipogenesis in adipose tissue. The concentration of hormone reaching a target cell is very low (picomolar to nanomolar) because of dilution in the blood — requiring high-affinity receptors and signal amplification. Endocrine signalling operates over minutes to hours and produces sustained, coordinated metabolic responses.
Contact-Dependent — Direct Cell-to-Cell Communication
Signal molecules remain tethered to the plasma membrane of the signalling cell and act only on cells in direct physical contact, through membrane-to-membrane interaction with cognate receptors. This allows the precise spatial resolution of signalling down to the level of individual cell-cell contacts — critical in developmental fate decisions. The Notch–Delta system is the paradigm: membrane-bound Notch receptors on one cell interact with membrane-bound Delta-like (Dll1, 3, 4) or Jagged ligands on an adjacent cell. Lateral inhibition through Notch–Delta generates alternating cell fates in Drosophila wing disc and vertebrate neural progenitor fields. Ephrin–Eph receptor interactions similarly require cell contact and guide axonal projections.
Direct Cytoplasmic Coupling — Small Molecules Through Channels
Connexin proteins form gap junction channels that directly connect the cytoplasm of adjacent cells, permitting the direct passage of small molecules (below ~1 kDa) and ions between cells without crossing the extracellular space. Ions (Ca²⁺, K⁺), second messengers (cAMP, IP3), amino acids, and nucleotides can all pass through gap junctions, enabling rapid electrical coupling and metabolic coordination between coupled cells. Gap junctions are critical in cardiac muscle (enabling action potential propagation between cardiomyocytes, coordinating the heartbeat), smooth muscle, the lens of the eye (which is avascular and relies on gap junction metabolite transfer), and gap junction-mediated Ca²⁺ waves in glial cells. Loss of gap junction communication is common in cancer and may contribute to tumour escape from tissue growth constraints.
Specialised Paracrine — Neurotransmission at Chemical Synapses
Chemical synaptic transmission is a highly specialised form of paracrine signalling in which a presynaptic neuron releases neurotransmitter into the synaptic cleft — the ~20 nm gap between pre- and postsynaptic membranes — in a tightly controlled, calcium-dependent exocytotic event. The confined geometry of the synaptic cleft enables very high local neurotransmitter concentrations (millimolar in the cleft), rapid receptor saturation (submillisecond), and rapid clearance (by reuptake transporters or enzymatic degradation). This achieves the speed and precision required for information processing in the nervous system. Different neurotransmitters and different postsynaptic receptor subtypes produce different postsynaptic responses — the diversity of synaptic signalling is the molecular basis of neural circuit computation.
Signal Molecules — Classification of First Messengers
The signal molecule — the first messenger, or ligand — is the initiating stimulus of every signalling event. Its chemical properties determine how it travels from its source to its receptor and which class of receptor it can engage. As StatPearls’ review of cellular messengers describes, cellular communication involves various biochemical steps and many different messenger molecules between cells and organs, with paracrine, endocrine, and autocrine pathways each employing molecules suited to their range and duration of action.
Receptor Classes — Architecture, Location, and Signalling Logic
Receptors are the molecular transducers of cell signalling — proteins whose ligand-binding domain precisely recognises its cognate signal molecule and whose structural or enzymatic domain initiates the intracellular response. Their classification by location and mechanism reflects the fundamental division between hydrophilic ligands (requiring cell-surface receptors) and hydrophobic ligands (permitting intracellular receptors).
Relative therapeutic importance of receptor classes — proportion of approved drug targets
G Protein-Coupled Receptors — the Largest and Most Druggable Receptor Family
G protein-coupled receptors (GPCRs) are seven-transmembrane (7-TM) proteins that constitute the single largest family of human cell-surface receptors — approximately 800 members encoded in the human genome, mediating responses to hormones, neurotransmitters, odorants, tastants, photons (through rhodopsin), and lipid mediators. Their shared structural architecture — seven membrane-spanning α-helices connected by alternating extracellular and intracellular loops, with an extracellular N-terminus and intracellular C-terminus — defines the family, while enormous sequence diversity in the ligand-binding pocket accounts for the breadth of their pharmacological targeting. GPCRs are the target of approximately 30% of FDA-approved drugs, making them the most therapeutically important receptor family in medicine.
The G Protein Cycle — Activation, Signalling, and Termination
The G protein cycle is the molecular heart of GPCR signalling. In the inactive state, the heterotrimeric G protein (Gα·GDP bound to Gβγ) is associated with the GPCR’s intracellular face. Ligand binding causes a conformational change propagated through the transmembrane helices to the intracellular loops, which serve as the receptor’s guanine nucleotide exchange factor (GEF) surface for Gα.
The activated receptor catalyses GDP release from Gα and GTP binding. GTP-bound Gα undergoes a conformational change that releases Gβγ, and both the GTP–Gα monomer and free Gβγ dimer can engage downstream effectors. GTP–Gα acts until its intrinsic GTPase activity hydrolyses GTP to GDP, returning it to the inactive Gα·GDP state and enabling re-association with Gβγ and receptor. This hydrolysis is rate-limiting and can be accelerated up to 1,000-fold by GTPase-accelerating proteins (GAPs) — in the GPCR context, these are the RGS (regulators of G-protein signalling) proteins, which are the primary mechanism for rapid signal termination.
The four major Gα families and their downstream effectors:
Gαs (stimulatory): activates adenylyl cyclase (AC) → ↑cAMP → activates PKA. Examples: β-adrenergic receptors (adrenaline → ↑heart rate), glucagon receptor (↑hepatic glucose production), TSH receptor, D1 dopamine receptor.
Gαi/o (inhibitory): inhibits adenylyl cyclase → ↓cAMP. Also activates GIRK channels (K⁺ efflux → hyperpolarisation). Examples: M2 muscarinic receptor (ACh → ↓heart rate), α2-adrenergic receptor, D2 dopamine receptor, μ-opioid receptor.
Gαq/11: activates phospholipase C-β (PLC-β) → PIP2 hydrolysis → IP3 + DAG → Ca²⁺ release + PKC activation. Examples: M1/M3 muscarinic receptors, α1-adrenergic receptor, angiotensin AT1 receptor, Gq-coupled thrombin receptor.
Gα12/13: activates Rho guanine nucleotide exchange factors (RhoGEFs) → RhoA activation → stress fibre formation, cytoskeletal contraction, and cell migration. Important in platelet activation, endothelial permeability, and cancer cell invasion.
Sustained GPCR stimulation triggers two coupled processes that attenuate signalling: desensitisation (uncoupling of receptor from G protein) and internalisation (removal of receptor from the cell surface). Upon prolonged activation, G protein-coupled receptor kinases (GRKs) phosphorylate serine and threonine residues on the receptor’s C-terminus and third intracellular loop. β-arrestin proteins then bind the phosphorylated receptor, sterically blocking further G protein coupling and recruiting the clathrin-mediated endocytic machinery, internalising the receptor into endosomes. In endosomes, receptors either recycle to the plasma membrane (resensitisation) or are sorted to lysosomes for degradation (downregulation). This desensitisation mechanism explains tachyphylaxis — the reduced response to repeated doses of a drug acting at a GPCR. Opioid desensitisation through this mechanism contributes to the development of tolerance requiring dose escalation.
Interestingly, β-arrestin binding also initiates G protein-independent signalling — activating ERK, PI3K, and Src through the β-arrestin scaffolding function. This “biased agonism” — drugs that selectively activate G protein or β-arrestin pathways — is an active area of therapeutic development aiming to separate desired effects from unwanted side effects in GPCR pharmacology.
Receptor Tyrosine Kinases — Growth Factor Receptors and Their Cascades
Receptor tyrosine kinases (RTKs) are a family of approximately 90 transmembrane proteins that combine growth factor binding and intracellular tyrosine kinase activity in a single polypeptide. They are the primary receptors for growth factors — EGF, insulin/IGF-1, PDGF, FGF, VEGF, NGFR, HGF — and their activation drives cell proliferation, survival, differentiation, and migration. RTKs are among the most commonly mutated proteins in cancer, and targeted kinase inhibitors directed against specific mutant RTKs represent the paradigm of precision oncology. As the NCBI’s intracellular signal transduction reference notes, cell surface receptors stimulate intracellular target enzymes either directly linked or coupled via G proteins, with these enzymes serving as downstream elements that propagate and amplify the initial signal.
Step 1 — Ligand Binding and Receptor Dimerisation
Growth factor binding to the extracellular domain of an RTK induces receptor dimerisation — the formation of a receptor homodimer (two identical receptor chains) or heterodimer (two different RTK family members). For most RTKs, the ligand brings two receptor molecules together, though different families employ distinct dimerisation mechanisms. EGFR dimerisation is driven by receptor conformational changes exposing a dimerisation arm; insulin receptor exists as a constitutive disulphide-linked dimer and undergoes a conformational rearrangement upon insulin binding. Some RTKs (e.g., VEGFR) require ligand-mediated receptor clustering. Dimerisation brings the intracellular tyrosine kinase domains of the two receptor chains into proximity — the prerequisite for transactivation.
Step 2 — Transautophosphorylation and Kinase Activation
The juxtaposed kinase domains of the dimerised RTK phosphorylate each other on specific tyrosine residues — a process called transautophosphorylation. Phosphorylation of tyrosines in the activation loop (typically Y1158, Y1162, Y1163 in the insulin receptor) stabilises the catalytically active conformation of the kinase domain, dramatically increasing its catalytic activity toward downstream substrates. Additional tyrosines in the juxtamembrane region, kinase insert, and C-terminal tail are phosphorylated as well — these phosphotyrosines serve as docking sites for SH2 domain-containing adaptor proteins and effectors that initiate downstream signalling cascades.
Step 3 — Adaptor Protein Recruitment and Signalosome Assembly
Specific phosphotyrosine sequences on the activated RTK are recognised by SH2 (Src homology 2) and PTB (phosphotyrosine-binding) domains of adaptor and signalling proteins. Each phosphotyrosine has a distinct surrounding sequence context that determines which SH2-domain protein binds — this creates a combinatorial code that determines which downstream pathways are activated. Key adaptors include: Grb2 (binds EGFR phosphotyrosine, recruits SOS GEF → Ras activation → MAPK/ERK); p85 PI3K regulatory subunit (binds RTK phosphotyrosines or IRS-1/2 docking proteins → PI3K activation → Akt); IRS-1/2 (insulin receptor substrates — phosphorylated by the insulin RTK, acting as multi-site scaffolds for PI3K and Grb2 recruitment); PLCγ (phosphorylates PIP2 → IP3 + DAG); Src family kinases. This multi-site signalosome assembly enables RTKs to activate multiple cascades simultaneously from a single activation event.
Step 4 — Divergent Downstream Cascade Activation
From the RTK signalosome, signalling diverges simultaneously into multiple pathways: the MAPK/ERK pathway (via Grb2/SOS/Ras → Raf → MEK → ERK → proliferation and differentiation genes); the PI3K/Akt/mTOR pathway (via p85-p110 PI3K → PIP3 → Akt → survival, metabolism, growth); PLCγ → IP3/DAG → Ca²⁺/PKC → diverse cytoplasmic and nuclear targets; and Src family kinases → additional tyrosine phosphorylation events and FAK activation for cell adhesion and migration. The relative activation of these branches, and their integration, depends on the specific RTK, its tissue context, the complement of adaptor proteins expressed, and the scaffold proteins providing spatial organisation.
Step 5 — Signal Termination — Phosphatases and Ubiquitination
RTK signalling is terminated by multiple mechanisms. Protein tyrosine phosphatases (PTPs) — including PTP1B, SHP-1, SHP-2, and PTEN — remove phosphate from RTK phosphotyrosines and downstream substrates, attenuating the signal. Ubiquitin ligase Cbl (recruited to activated RTKs via its SH2 domain) ubiquitinates the RTK, targeting it for endocytosis and subsequent lysosomal degradation — removing the receptor from the signalling-competent membrane pool. Negative feedback within cascades: MAPK activation of Spry proteins (which inhibit Ras/Raf), ERK phosphorylation of SOS (reducing its GEF activity), and S6K phosphorylation of IRS-1 (reducing insulin receptor substrate sensitivity) all create negative feedback loops that self-limit signal duration.
Ligand-Gated Ion Channels — Fastest Signalling in the Nervous System
Ligand-gated ion channels (LGICs, also called ionotropic receptors) are transmembrane proteins that combine ligand-binding and ion channel functions in a single molecular complex — when a neurotransmitter binds, the channel opens within microseconds, permitting the rapid passage of specific ions down their electrochemical gradient. This is the fastest form of cell signalling — orders of magnitude faster than any second-messenger cascade — and it underlies virtually all fast synaptic transmission in the central and peripheral nervous systems.
| Channel / Receptor | Ligand | Ion(s) Permeant | Effect | Clinical Relevance |
|---|---|---|---|---|
| nAChR (nicotinic acetylcholine receptor) | Acetylcholine; nicotine | Na⁺ (in), K⁺ (out), Ca²⁺ (in) | Depolarisation — excitatory. Fast EPSPs at NMJ and autonomic ganglia | Curare/rocuronium block NMJ nAChRs → muscle relaxation in anaesthesia. Myasthenia gravis: autoantibodies against nAChR |
| NMDA receptor (NR1/NR2) | Glutamate + glycine (co-agonist); requires membrane depolarisation to relieve Mg²⁺ block | Na⁺ (in), K⁺ (out), Ca²⁺ (in) | Coincidence detector — requires simultaneous presynaptic glutamate release and postsynaptic depolarisation. Mediates LTP (memory formation) | Ketamine/memantine: NMDA channel blockers. Phencyclidine (PCP). NMDA autoencephalitis (anti-NR1 antibodies) |
| AMPA receptor | Glutamate | Na⁺ (in), K⁺ (out); [Ca²⁺ permeant when GluA2-lacking] | Fast excitatory synaptic transmission. AMPA trafficking underlies LTP expression | AMPA autoencephalitis. Perampanel: AMPA antagonist anticonvulsant |
| GABA-A receptor | GABA (γ-aminobutyric acid); benzodiazepines; barbiturates; general anaesthetics (allosteric) | Cl⁻ (in) → hyperpolarisation | Primary fast inhibitory neurotransmission in the CNS | Benzodiazepines (positive allosteric modulators → ↑Cl⁻ conductance → anxiolysis, sedation). Barbiturates. Propofol |
| Glycine receptor | Glycine | Cl⁻ (in) → hyperpolarisation | Primary fast inhibitory transmission in spinal cord and brainstem | Tetanus toxin blocks glycine release → spastic paralysis. Strychnine: glycine receptor antagonist → convulsions |
| 5-HT₃ receptor | Serotonin (5-hydroxytryptamine) | Na⁺ (in), K⁺ (out), Ca²⁺ (in) | Depolarisation — excitatory. Present on vagal afferents and in gut enteric nervous system | Ondansetron: 5-HT₃ antagonist — gold standard anti-emetic for chemotherapy-induced nausea |
| P2X receptors | ATP (extracellular) | Na⁺ (in), K⁺ (out), Ca²⁺ (in) | Depolarisation — pain signalling, purinergic neurotransmission | P2X3 antagonist gefapixant: treatment of chronic cough. Pain pathway modulation |
Intracellular and Nuclear Receptors — Gene Regulation by Hydrophobic Signals
Intracellular receptors — the nuclear receptor superfamily — are ligand-regulated transcription factors that reside in the cytoplasm or nucleus and are activated by small, lipid-soluble molecules that cross the plasma membrane. With 48 members in the human genome, they constitute a relatively small but pharmacologically crucial receptor family: steroid hormones, thyroid hormones, vitamin D, retinoic acid, and fatty acids all signal through nuclear receptors, and this family is the target of approximately 16% of approved drugs.
Mechanism of Nuclear Receptor Activation
In the absence of ligand, many nuclear receptors (especially steroid receptors in the cytoplasm) are maintained in an inactive complex with heat shock proteins (HSP90, HSP70, p23) that prevent nuclear translocation. Ligand binding induces a conformational change in the ligand-binding domain (LBD), repositioning helix 12 (the activation function 2 helix, AF-2) to create a co-activator binding surface and releasing the heat shock protein chaperone complex. The activated receptor then translocates to the nucleus (or, for thyroid/retinoid receptors already in the nucleus, undergoes the conformational change directly) and binds to specific DNA regulatory sequences — hormone response elements (HREs) — typically as homodimers (steroid receptors) or heterodimers with RXR (thyroid, retinoid, vitamin D receptors). Liganded nuclear receptors recruit co-activator complexes (p160 family: SRC-1, GRIP-1/TIF2, p/CIP) that possess or recruit histone acetyltransferase (HAT) activity, opening chromatin at target gene promoters and enabling transcription. Unliganded receptors often associate with co-repressor complexes (NCoR, SMRT) and histone deacetylase (HDAC) activity, maintaining target gene repression.
Nuclear Receptor Pharmacology
The nuclear receptor family is among the most successfully drugged in medicine. Glucocorticoid receptor (GR): corticosteroids (prednisolone, dexamethasone) activate GR → powerful anti-inflammatory and immunosuppressive gene expression programme. The most prescribed class of anti-inflammatory drugs globally — and the most common cause of secondary osteoporosis through suppression of osteoblast differentiation. Oestrogen receptor (ERα): oestrogens drive breast cancer in ERα+ tumours; tamoxifen (selective ER modulator, SERM — acts as antagonist in breast, agonist in bone and uterus) and aromatase inhibitors (anastrozole, letrozole) are the backbone of hormonal breast cancer therapy. Androgen receptor (AR): prostate cancer is initially androgen-dependent; enzalutamide (AR antagonist) and abiraterone (androgen synthesis inhibitor) form the current standard of care. PPARγ: thiazolidinediones (pioglitazone, rosiglitazone) activate PPARγ → insulin-sensitising gene programme → type 2 diabetes treatment. FXR: bile acid receptor; obeticholic acid (FXR agonist) is approved for primary biliary cholangitis.
Second Messengers — the Intracellular Amplifiers of Cell Signalling
Second messengers solve a fundamental problem in cell signalling: a receptor at the cell surface receives one molecule of ligand, but needs to activate thousands of intracellular targets simultaneously to produce a meaningful cellular response. Small, diffusible intracellular molecules — second messengers — are generated rapidly and in large quantities from receptor activation, spreading the signal throughout the cell and activating multiple effector proteins in parallel. Each second messenger has specific effector proteins it activates, a specific mechanism of generation, and a specific degradation mechanism that terminates the signal.
cAMP — Cyclic Adenosine Monophosphate: Generation: Adenylyl cyclase (AC) converts ATP → cAMP + PPi Activated by: Gαs-coupled GPCRs (β-AR, glucagon-R, D1-R, TSH-R, EP2/EP4) Inhibited by: Gαi-coupled GPCRs (α2-AR, M2-R, D2-R, μ-opioid) Key effectors: PKA (cAMP-dep. protein kinase A) → phosphorylates CREB, glycogen phosphorylase, lipase EPAC (exchange protein activated by cAMP) → Rap1 GEF HCN channels (funny current in cardiac pacemakers) Termination: Phosphodiesterases (PDEs) hydrolyse cAMP → 5'-AMP Drug targets: Caffeine/theophylline (PDE inhibitors → ↑cAMP); Sildenafil (PDE5 inhibitor → ↑cGMP) IP3/DAG — PLC Products from PIP2 Hydrolysis: Generation: PLC-β (Gαq-activated) or PLC-γ (RTK-activated) cleaves PIP2 → IP3 + DAG IP3 targets: IP3R (inositol trisphosphate receptor) on ER → Ca²⁺ release into cytoplasm DAG targets: PKC (protein kinase C) — requires Ca²⁺ + DAG for classical isoforms DAG lipase → arachidonic acid → prostaglandins/leukotrienes Termination: IP3 phosphorylated to IP4 by IP3 kinase; DAG phosphorylated to phosphatidic acid by DAG kinase Ca²⁺ — Intracellular Calcium as Second Messenger: Resting [Ca²⁺]i: ~100 nM (cytoplasm) vs 1.2 mM (extracellular) — 10,000-fold gradient Release routes: IP3R (ER) and RyR (ER/SR in muscle) → release from stores Plasma membrane: VGCC, NMDA-R, TRPC channels, SOCE (Orai/STIM) Key effectors: Calmodulin (CaM) → CaM kinases (CAMKII — LTP, memory formation) Calcineurin → dephosphorylates NFAT → immune gene expression Troponin C → muscle contraction; Calpain → protease activation Termination: SERCA pump → Ca²⁺ back into ER; PMCA pump → Ca²⁺ out of cell; NCX exchanger PIP3 — Phosphatidylinositol (3,4,5)-trisphosphate: Generation: PI3-kinase (class I PI3K: p110α/β/γ/δ + regulatory p85 or p101) phosphorylates PIP2 → PIP3 Key effectors: PDK1 + Akt → cell survival, proliferation, metabolism (PI3K/Akt/mTOR axis) Termination: PTEN phosphatase: dephosphorylates PIP3 → PIP2 [tumour suppressor] SHIP phosphatase: dephosphorylates PIP3 → PI(3,4)P2
The MAPK/ERK Pathway — the Growth and Proliferation Cascade
The mitogen-activated protein kinase / extracellular signal-regulated kinase (MAPK/ERK) pathway is one of the most conserved, best-characterised, and most clinically important signalling cascades in biology. Present in all eukaryotes from yeast to humans, it transmits growth factor signals from RTKs and some GPCRs through a sequential kinase cascade to transcription factors in the nucleus, controlling cell proliferation, differentiation, survival, senescence, and migration. It is the most frequently activated pathway in cancer — estimated to be dysregulated in approximately 40% of all human cancers.
Of all human cancers carry MAPK pathway mutations — the most frequently activated oncogenic pathway, dominated by KRAS, NRAS, BRAF, and upstream RTK amplifications
KRAS alone is mutated in ~90% of pancreatic ductal adenocarcinomas, ~45% of colorectal cancers, and ~25% of non-small cell lung cancers. For decades, KRAS was considered “undruggable” due to the absence of obvious drug-binding pockets; the approval of sotorasib (AMG 510) in 2021 — the first KRAS-specific inhibitor — targeting KRAS G12C marked a turning point in oncology. BRAF V600E is present in ~50% of melanomas and targeted by vemurafenib/dabrafenib (BRAF inhibitors) combined with cobimetinib/trametinib (MEK inhibitors) — achieving response rates exceeding 60% but limited by resistance mechanisms. MEK inhibitors alone target the cascade one step below BRAF, offering activity against BRAF-mutant and certain KRAS-driven tumours.
The Core MAPK/ERK Cascade — Ras to Nucleus
The canonical MAPK/ERK cascade is a three-tier kinase module in which each kinase activates the next through phosphorylation, creating a signal amplification cascade with each tier:
Ras Activation — the Molecular Switch
Ras (RAS proto-oncogene, small GTPase) is the key molecular switch of the pathway. In the inactive state, Ras is GDP-bound and plasma membrane-anchored via a farnesyl modification. RTK activation recruits the Grb2/SOS complex to the plasma membrane, where SOS acts as a guanine nucleotide exchange factor (GEF) for Ras, catalysing GDP release and GTP binding. GTP-bound Ras undergoes a conformational change in switch I and switch II regions that creates an effector-binding surface, allowing Ras to engage downstream effectors — primarily Raf, PI3K, and RalGDS. The intrinsic GTPase activity of Ras hydrolyses GTP to GDP (rate-limited by the RasGAP protein neurofibromin — encoded by NF1, frequently mutated in neurofibromatosis). Oncogenic KRAS G12D, G12V, G12C mutations abolish GTPase activity, constitutively locking Ras in the GTP-bound active state and permanently activating downstream proliferative signalling.
Raf Activation — MAP3K Level
Active GTP-bound Ras recruits Raf kinase (MAP3K level — MAPK kinase kinase) to the plasma membrane. The Raf family includes ARAF, BRAF, and CRAF (Raf-1). BRAF has the highest intrinsic kinase activity and is most directly activated by Ras; CRAF requires additional phosphorylation events. Raf is activated by plasma membrane recruitment (relieving an autoinhibitory intramolecular interaction), Ras binding, phosphorylation at Ser338 and Tyr341 by Src and PAK, and dimerisation. The oncogenic BRAF V600E mutation (glutamic acid at position 600 mimics phosphorylation) constitutively activates BRAF kinase independently of Ras — explaining why BRAF V600E tumours retain sensitivity to BRAF inhibitors even when upstream Ras is not mutated.
MEK1/2 Activation — MAP2K Level
Active Raf phosphorylates and activates MEK1 and MEK2 (MAPK kinase; MAP2K level) on Ser218 and Ser222 in their activation loops. MEK is a dual-specificity kinase — it phosphorylates both threonine and tyrosine residues on its substrate ERK (at Thr202/Tyr204 in ERK1, Thr185/Tyr187 in ERK2). MEK is extremely selective — ERK1/2 are its only known physiological substrates in the canonical MAPK cascade. This selectivity makes MEK an attractive drug target: MEK inhibitors (trametinib, cobimetinib, binimetinib) inhibit the pathway regardless of the upstream oncogenic driver (BRAF, KRAS, or other MAPK activators) and are used in combination with BRAF inhibitors in melanoma and other BRAF-mutant cancers.
ERK1/2 Activation and Nuclear Translocation — the Output Kinase
Phosphorylated ERK1/2 (MAPK level) are the principal output kinases of the cascade, with more than 300 cytoplasmic and nuclear substrates identified. Once activated, ERK dimerises and translocates to the nucleus, where it phosphorylates and activates transcription factors including Elk-1 (inducing c-Fos expression), RSK family kinases (which phosphorylate CREB → CRE-dependent gene transcription), and c-Myc (phosphorylation stabilises it, driving a proliferative transcriptional programme). ERK-dependent gene targets include D-type cyclins (promoting G1/S cell cycle transition), c-Fos/Jun (AP-1 transcription factor complex), and numerous growth and survival genes. Cytoplasmic ERK substrates include RSK (promoting translation via S6 phosphorylation), cytoskeletal proteins, and other kinases. Negative feedback occurs through ERK phosphorylation of upstream SOS, inhibiting Ras re-activation, and through induction of DUSP (dual-specificity phosphatase) expression that dephosphorylates and inactivates ERK.
The PI3K/Akt/mTOR Pathway — Survival, Growth, and Metabolism
The phosphoinositide 3-kinase (PI3K) / Akt / mammalian target of rapamycin (mTOR) pathway is the principal intracellular signalling axis governing cell survival, growth, protein synthesis, and metabolism. It is activated downstream of most RTKs and many GPCRs, and is the second most commonly mutated pathway in cancer after the MAPK pathway — with mutations affecting PI3KCA (encoding the p110α catalytic subunit of PI3K), PTEN, AKT, and mTOR found collectively in >30% of all solid tumours.
Generating the PIP3 Second Messenger
Class I PI3Ks are heterodimers of a catalytic subunit (p110α, p110β, p110γ, or p110δ) and a regulatory subunit (p85α/β/γ or p101/p84). Upon RTK activation, the p85 regulatory subunit’s SH2 domain binds receptor phosphotyrosines or adaptor proteins (IRS-1/2), recruiting the p110 catalytic subunit to the plasma membrane where its substrate PIP2 is localised. PI3K phosphorylates PIP2 at the 3-position of the inositol ring, generating PIP3 — a lipid second messenger anchored in the inner leaflet of the plasma membrane. PI3KCA (p110α) is the most frequently mutated oncogene in breast cancer, with hotspot mutations H1047R and E542K/E545K constitutively activating PI3K regardless of upstream receptor signalling.
The Brake — Tumour Suppressor Phosphatase
PTEN (phosphatase and tensin homologue) is the primary antagonist of PI3K signalling — it dephosphorylates PIP3 at the 3-position, reversing PI3K activity and reducing PIP3 levels. PTEN is the second most commonly mutated tumour suppressor gene after TP53 — it is deleted or mutated in ~30% of glioblastomas, ~40% of endometrial cancers, ~25% of prostate cancers, and at lower frequencies across most cancer types. Its loss constitutively activates Akt even in the absence of growth factor stimulation, providing sustained survival and proliferative signalling. In Cowden syndrome (germline PTEN mutation), patients develop multiple hamartomas and are at high risk of breast, thyroid, and endometrial cancers.
The Survival Kinase
Akt (protein kinase B) is a serine/threonine kinase with three isoforms (Akt1, Akt2, Akt3) that is the primary mediator of PI3K’s survival and metabolic signals. PIP3 recruits Akt to the plasma membrane through its PH domain; PDK1 (pyruvate dehydrogenase kinase 1, also recruited by PIP3) phosphorylates Akt at Thr308 in the activation loop; mTORC2 phosphorylates Akt at Ser473 — both phosphorylations required for full activity. Active Akt phosphorylates and inactivates pro-apoptotic proteins Bad (preventing cytochrome c release) and FOXO transcription factors (preventing expression of pro-apoptotic and cell cycle inhibitory genes); activates eNOS; phosphorylates and inactivates TSC2 (tuberous sclerosis complex protein 2), relieving its inhibition of Rheb → activating mTORC1.
Integrating Growth Signals with Nutrient Status
mTOR (mechanistic target of rapamycin) is a large serine/threonine kinase that forms two structurally and functionally distinct complexes: mTORC1 (with Raptor — rapamycin-sensitive; integrates growth factor signals, amino acid availability, and energy status to control protein synthesis, autophagy, and cell cycle) and mTORC2 (with Rictor — rapamycin-insensitive; phosphorylates Akt at Ser473 and PKC). mTORC1 promotes anabolic processes: it phosphorylates S6K1 (activating ribosome biogenesis and translation initiation) and 4EBP1 (releasing the cap-binding protein eIF4E to initiate cap-dependent translation). Rapamycin (sirolimus) allosterically inhibits mTORC1 and is used clinically as an immunosuppressant (preventing organ rejection) and as an anti-cancer agent (everolimus for renal cell carcinoma, breast cancer, neuroendocrine tumours). mTOR is also the terminal effector of the energy-sensing pathway involving AMPK — low cellular ATP activates AMPK, which phosphorylates and activates TSC2 (inhibiting mTORC1) and directly phosphorylates Raptor (inhibiting mTORC1), coupling energy sensing to protein synthesis rate.
The JAK/STAT Pathway — Cytokine Signalling to the Nucleus
The Janus kinase (JAK) / Signal Transducer and Activator of Transcription (STAT) pathway transmits signals from cytokines, interferons, and certain growth factors directly from the plasma membrane to the nucleus, with a simplicity and speed unmatched by most other signalling cascades — the same kinases that are activated at the receptor are those that directly phosphorylate the transcription factors that enter the nucleus. Its discovery by James Darnell, Ian Kerr, and George Stark — work for which they received the Lasker Award in 1997 — revealed a fundamentally new paradigm of receptor-to-nucleus signalling.
The JAK/STAT pathway is among the most streamlined receptor-to-nucleus routes in signal transduction — the same molecules that detect the cytokine at the membrane directly modify gene expression in the nucleus, with no intermediary second messenger and with a minimum of molecular steps between ligand and genomic response.
Reflecting the structural simplicity of the JAK/STAT pathway relative to MAPK and PI3K cascades, as characterised by Darnell, Kerr, and Stark in the interferon signalling studies of the early 1990s
The discovery that JAK2 V617F — a single point mutation causing constitutive JAK2 activation — is present in >95% of polycythaemia vera and >50% of other myeloproliferative neoplasms transformed myeloid haematology overnight, converting a heterogeneous group of bone marrow disorders into targetable molecular diseases amenable to JAK inhibitor therapy.
Reflecting the concurrent 2005 reports from five independent groups identifying JAK2 V617F, and the subsequent development of ruxolitinib (JAK1/2 inhibitor) as the first approved targeted therapy for myelofibrosis and polycythaemia vera
The JAK/STAT Signalling Sequence — Step by Step
Cytokine binding causes receptor dimerisation (or conformational change in pre-existing dimers), bringing together the JAK kinases associated with each receptor chain. JAKs transphosphorylate each other and the receptor cytoplasmic tails on specific tyrosine residues — creating phosphotyrosine docking sites for STAT SH2 domains. STAT monomers bind receptor phosphotyrosines, are themselves phosphorylated by JAKs on a critical C-terminal tyrosine (Tyr701 in STAT1, Tyr705 in STAT3), and phospho-STATs dimerize through reciprocal SH2–phosphotyrosine interactions. Dimers translocate to the nucleus and bind palindromic DNA elements — ISRE (for STAT1/2/3 activated by interferons) or GAS elements (for most STATs). STAT-dependent gene transcription produces effector proteins, many of which are negative regulators initiating feedback: SOCS1 and SOCS3 (suppressors of cytokine signalling — bind JAKs and inhibit their activity, and bind phosphotyrosines on receptors to compete with STATs), PIAS proteins (protein inhibitors of activated STAT — SUMO ligases that modify STATs reducing their DNA-binding activity), and PTP1B (dephosphorylates JAK2 and the insulin receptor).
Clinically approved JAK inhibitors — ruxolitinib (JAK1/2), baricitinib (JAK1/2), tofacitinib (JAK1/3), upadacitinib (JAK1), filgotinib (JAK1) — are used in myeloproliferative neoplasms, rheumatoid arthritis, atopic dermatitis, inflammatory bowel disease, and alopecia areata, demonstrating the breadth of JAK/STAT pathway importance across haematology and immunology.
Wnt/β-Catenin Signalling — Stem Cells, Development, and Cancer
The Wnt signalling pathway is a highly conserved developmental pathway present in all metazoans, governing embryonic patterning, stem cell self-renewal, and tissue homeostasis throughout life. Its canonical branch — the Wnt/β-catenin pathway — controls the stability and nuclear translocation of β-catenin, a dual-function protein that acts both as a component of the adherens junction cadherin–catenin adhesion complex and as a transcriptional co-activator in the nucleus. Aberrant Wnt/β-catenin activation is the driver of approximately 90% of colorectal cancers (through mutations in APC or β-catenin itself) and contributes to hepatocellular carcinoma, medulloblastoma, and other malignancies.
Notch Signalling — Juxtacrine Fate Decisions
Notch is a cell-surface receptor that mediates juxtacrine signalling — it can only be activated by contact with a ligand on an immediately adjacent cell, making it the prototypic contact-dependent developmental pathway. The Notch pathway governs binary cell fate decisions during development and throughout adult tissue homeostasis, controlling the balance between stem cell self-renewal and differentiation in numerous tissue types including the intestinal epithelium, haematopoietic system, vasculature, and nervous system. Its defining feature as a signalling mechanism is its remarkable directness — there are no second messengers and no kinase cascades; the receptor itself, after ligand-induced proteolysis, generates the transcriptional activator that enters the nucleus.
Notch Activation by Sequential Proteolysis
Notch receptors (NOTCH1–4) are large single-pass transmembrane proteins that, during their biosynthesis, are cleaved in the Golgi by furin protease (S1 cleavage) to produce a non-covalently associated heterodimer at the cell surface. Upon contact with Dll/Jagged ligands on adjacent cells, ADAM-family metalloproteases (ADAM10/TACE) perform ectodomain shedding (S2 cleavage). The remaining membrane-bound stub is then cleaved within its transmembrane domain by the γ-secretase complex (presenilin + nicastrin + Aph1 + Pen2) — the S3 cleavage — releasing the Notch intracellular domain (NICD) into the cytoplasm. NICD translocates to the nucleus, where it binds the transcriptional repressor CSL/RBPjκ and converts it to a transcriptional activator by displacing co-repressors and recruiting the co-activator Mastermind-like (MAML). Active NICD/CSL/MAML complexes drive Notch target gene transcription.
Lateral Inhibition — Binary Fate Specification
Notch–Delta lateral inhibition is the mechanism by which equivalent progenitor cells adopt different fates based on small, stochastic initial differences in Delta ligand expression. A cell with slightly more Delta expression activates Notch in its neighbour, which upregulates Notch targets that suppress Delta expression — reducing its ability to activate Notch in the first cell. This mutual inhibition creates a positive feedback loop that amplifies initial differences, ultimately producing an alternating mosaic of two cell types from a field of equivalent progenitors. Examples: neural stem cells vs. neurons in Drosophila and vertebrate neurogenesis; intestinal secretory (Atoh1+) vs. absorptive (Hes1+) progenitor specification; arterial vs. venous endothelial specification through Delta4–Notch1 lateral inhibition.
Notch in Disease and Therapy
NOTCH1 gain-of-function mutations occur in >60% of T-cell acute lymphoblastic leukaemia (T-ALL), making it a prime therapeutic target. Alagille syndrome (germline JAGGED1 or NOTCH2 mutation) causes bile duct paucity, cardiac defects, and facial features. CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is caused by NOTCH3 EGF-domain mutations. γ-Secretase inhibitors (GSIs) — which block the final cleavage releasing NICD — have been extensively investigated in T-ALL, but gastrointestinal toxicity from Notch inhibition in the intestinal stem cell niche has limited clinical utility.
Hedgehog Signalling — the Developmental Morphogen Pathway
The Hedgehog (Hh) signalling pathway — named for the Drosophila segment polarity phenotype in which its disruption causes spiky bristle patterns resembling a hedgehog — is a critical developmental morphogen pathway governing embryonic patterning of the limbs, neural tube, face, and gut. In adult tissues it maintains progenitor populations in the skin, gut, brain, and bone marrow. Its dysregulation drives basal cell carcinoma (BCC) — the most common cancer in humans — as well as medulloblastoma, rhabdomyosarcoma, and pancreatic cancer.
Hh Pathway in the OFF State — Ptch Represses Smo
In the absence of Hedgehog ligand, the 12-pass transmembrane receptor Patched (Ptch1) constitutively represses the 7-pass transmembrane protein Smoothened (Smo) — not through direct contact but through an unknown indirect mechanism possibly involving oxysterol transport. Repressed Smo remains in intracellular vesicles, unable to signal. In the primary cilium — an organelle critical for Hh signal transduction in vertebrates — the GLI transcription factors (GLI1, GLI2, GLI3) are processed: GLI3 and GLI2 are phosphorylated by PKA, CK1, and GSK3β, ubiquitinated, and partially degraded by the proteasome to generate repressor forms (GLI3R, GLI2R) that enter the nucleus and repress Hh target genes. The net effect is transcriptional repression of all Hh target genes.
Hh Pathway in the ON State — Smo Active, Gli Activators
Hedgehog ligands (Sonic Hh, Desert Hh, Indian Hh in vertebrates) bind and inhibit Ptch1, relieving its inhibition of Smo. Smo accumulates in the primary cilium membrane, where it becomes activated and recruits the GPCR kinase 2 (GRK2) and β-arrestin, promoting GLI2 and GLI3 processing toward their activator forms (GLIA) rather than repressor forms. Gli activators enter the nucleus and activate Hh target gene transcription: PTCH1 (negative feedback), GLI1 (amplification), SNAI1/2 (epithelial-mesenchymal transition), CCND1 (Cyclin D1 — cell cycle), VEGF (angiogenesis), and BCL2 (survival). Vismodegib and sonidegib (Smo inhibitors — first class of Hh pathway-targeted drugs, approved for advanced BCC) exploit the essential role of Smo in pathway activation. Resistance frequently occurs through Smo mutations that prevent drug binding or through downstream GLI amplification.
Signal Amplification, Integration, and Crosstalk
Individual signalling pathways do not operate in isolation — they are extensively interconnected through shared components, mutual regulatory nodes, and direct molecular interactions that create a network far more complex and responsive than any individual cascade. Signal amplification and pathway crosstalk are not incidental features of cell signalling — they are essential properties that enable the remarkable sensitivity, specificity, and dynamic range of cellular responses to environmental signals.
The signal amplification provided by intracellular cascades is staggering. The canonical example is the adrenaline-to-glycogen pathway: one adrenaline molecule binds one β-adrenergic receptor, which activates up to 100 molecules of Gs. Each Gs activates one adenylyl cyclase molecule, which generates thousands of cAMP molecules per minute. Each cAMP activates PKA, and each PKA molecule phosphorylates hundreds of phosphorylase kinase molecules per minute. Each activated phosphorylase kinase phosphorylates hundreds of glycogen phosphorylase molecules. The net result: a single adrenaline molecule triggers the liberation of millions of glucose molecules from glycogen within seconds. This cascade amplification — each enzyme in the chain catalysing the activation of many molecules of the next — means cells can respond to ligand concentrations in the picomolar range while producing metabolically significant outputs.
Signal amplification also explains the paradox of oncogenesis: a single activating mutation in a signalling enzyme can produce enough constitutive pathway output to drive transformation even when thousands of copies of wild-type protein are present. BRAF V600E constitutively phosphorylates MEK at a rate far exceeding normal stimulated wild-type BRAF, overwhelm the normal regulatory capacity of the cell.
Parallel Activation and Mutual Modulation
Both the MAPK/ERK and PI3K/Akt pathways are activated simultaneously downstream of RTKs and share both activating inputs (Ras activates both Raf and PI3K; Gβγ can activate PI3Kγ) and regulatory interactions. PI3K/Akt can activate mTORC1 → S6K1 → phosphorylation of IRS-1 on serine residues → reduced IRS-1 activity → reduced PI3K activation (negative feedback on its own upstream activator). ERK → RSK → phosphorylation of TSC2 → mTORC1 activation (positive input from MAPK to mTOR). Akt phosphorylates and inhibits Raf, reducing MAPK activity — one reason why PI3K inhibition can paradoxically activate MAPK signalling, creating the rational basis for combined MAPK + PI3K inhibition in cancer therapy.
Inflammation Meets Survival Signalling
Nuclear factor kappa-B (NF-κB) — activated by inflammatory cytokines (TNF-α, IL-1β), pattern recognition receptors (Toll-like receptors), and antigen receptors — intersects with almost every major signalling pathway. Akt phosphorylates and activates IKKα (IκB kinase), linking RTK survival signals to NF-κB activation. EGFR/ErbB2 signalling in cancer drives NF-κB-dependent anti-apoptotic gene expression (BCL-XL, survivin, XIAP), contributing to drug resistance. NF-κB and STAT3 form a particularly important oncogenic partnership — individually transient, together creating a sustained transcriptional activation of survival and proliferative genes that characterises many inflammation-associated cancers (hepatocellular carcinoma on cirrhotic backgrounds, gastric cancer in H. pylori infection).
Negative Feedback Maintains Signal Fidelity
Negative feedback — where pathway outputs inhibit upstream pathway components — is ubiquitous in signalling and essential for preventing runaway, uncontrolled activation. ERK phosphorylates SOS → reduces Ras activation; ERK induces DUSP expression → dephosphorylates ERK (negative autofeedback); S6K1 phosphorylates IRS-1 → reduces PI3K activation; JAK-induced SOCS expression → inhibits JAK activity; Notch-induced Numb → inhibits Notch; Wnt-induced Axin2 → promotes destruction complex → reduces β-catenin. Negative feedback is frequently disrupted in cancer — silencing of negative feedback genes maintains constitutive pathway activity even when the primary oncogenic driver is pharmacologically inhibited, contributing to drug resistance.
Spatial Organisation of Signalling Complexes
Scaffold proteins organise signalling components into localised complexes that enhance signalling efficiency, specificity, and speed. KSR1/2 (kinase suppressor of Ras) scaffolds Raf, MEK, and ERK together, concentrating the cascade at the plasma membrane and facilitating sequential phosphorylation. AKAP (A-kinase anchoring proteins) anchor PKA to specific cellular compartments (mitochondria, centrosome, postsynaptic density), directing cAMP-PKA signalling to specific substrates rather than allowing diffuse activation throughout the cell. β-Arrestin scaffolds ERK, Src, and other kinases for GPCR-dependent ERK activation at endosomes. IQ motif-containing GTPase-activating proteins (IQGAP) scaffold EGFR, VEGFR, Ras, Raf, MEK, and ERK at the leading edge of migrating cells. Scaffold proteins thus provide the spatial dimension of signalling specificity — the same kinase cascade can produce different outcomes when operating at the plasma membrane versus an endosome versus the nucleus.
Clinical Relevance — Cancer, Metabolic Disease, and Immunological Disorders
The clinical importance of cell signalling science is immense — virtually every pharmacological target in modern medicine is a signalling pathway component. The shift from empirical drug discovery to mechanism-based targeted therapy over the past three decades has been driven entirely by advances in understanding signalling pathways at the molecular level.
Cell Signalling Academic Support — Every Level, Every Pathway
From A-Level biology essays on receptor mechanisms and signal transduction to undergraduate biochemistry assignments on MAPK and PI3K cascades, medical school pharmacology, and postgraduate dissertation research in cancer signalling and drug resistance — our specialist team covers every pathway, every concept, and every academic level.
Frequently Asked Questions About Cell Signalling
Explore further support: biology assignments · chemistry & biochemistry help · biology research papers · lab reports · nursing assignments · dissertations and theses · science writing · data analysis · biostatistics · complex technical assignments · critical analysis papers · citation and referencing · proofreading and editing · literature reviews
